Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with or without chemotherapy for high-risk or advanced endometrial carcinoma
ACTRN12609000369224Phase 3Active, not recruiting
- Sponsor
- The University of Sydney
- Start
- Nov 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of cisplatin, carboplatin and paclitaxel in endometrial cancer (EC) (2 arms), sponsored by The University of Sydney. Primary endpoints: Five-year overall survival and Five-year failure-free survival. Started Nov 2008; status: active, not recruiting.
02
Drugs
cisplatincarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ACTRN12609000369224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000369224.